Drugs affected by FAAH
About FAAH
FAAH breaks down anandamide and other endocannabinoids, the body's own cannabinoid signals. A common variant (Pro129Thr, rs324420) reduces enzyme activity, leaving endocannabinoid tone slightly elevated. Studies have linked it to differences in pain perception, anxiety, and how people respond to cannabis and to FAAH-inhibitor drugs in development.[1]
FAAH is an active research area. The effects on any specific medication are modest, but the gene is included because endocannabinoid pharmacology is a fast-moving field.
What we test for FAAH
Gene2Rx uses definitions covering 2 named FAAH alleles, built from 1 variant in Gene2Rx definitions. Results depend on the variants available in your upload.
- Named alleles
- 2
- Defined variants
- 1
- Source
- Gene2Rx definitions
- Genome build
- GRCh38
- Normal Function 1
- Decreased Function 1
What do these allele names mean?
FAAH alleles are named by the underlying DNA variant rather than a star number. For example, c.61C>T describes a single base change at position 61 of the coding sequence.
DNA variant labels identify sequence differences. Their interpretation depends on the particular gene, the evidence, and the variants that can be assessed in your data. A DNA result does not directly measure enzyme activity.
The source of these definitions is listed above. Missing variants or incomplete coverage can leave a result indeterminate.
Medications with FAAH information
This list contains 1 medication with FAAH information from the sources shown below. Evidence and report eligibility differ by drug; each page explains its scope and limitations.
References
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
Explore FAAH in your report
Informational only, not medical advice. The presence of a FAAH pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.